PARADIGM Mentors

Pharmacogenomics

Julie A Johnson

Julie A Johnson Pharm.D.

Dean & Distinguished Professor
Department: Dean's Office
Phone: (352) 273-6309

Julie A. Johnson, Pharm.D., is dean of the University of Florida College of Pharmacy and distinguished professor of Pharmacy and Medicine. She received her B.S. in Pharmacy from the Ohio State University and her Pharm.D. from the University of Texas at Austin and the UT Health Science Center at San Antonio. She completed a post-doctoral fellowship in cardiovascular pharmacology/pharmacokinetics at Ohio State.

Johnson’s research focuses on cardiovascular pharmacogenomics and genomic medicine implementation. She is an internationally-recognized leader in pharmacogenomics and genomic medicine, with over 300 peer reviewed publications and nearly $50 million in research funding as principal investigator. In 2015, 2016, 2017 she was named a Thomson Reuters (now Clarivate Analytics) Highly Cited Scientist in Pharmacology and Toxicology, and in 2018 in the Cross Discipline category, indicating she is in the top 1% of the most highly cited scientists in the field globally.

Johnson has served on the Nonprescription Drugs Advisory Committee of the FDA, the XNDA Study Section at NIH, and in numerous scientific capacities with NIH’s NHLBI. She has had leadership roles in the American College of Clinical Pharmacy (ACCP), the American Heart Association (AHA), and the American Society of Clinical Pharmacology and Therapeutics (ASCPT), for which she completed her term as President in 2017. She is an elected fellow of the ACCP, the AHA and the American College of Clinical Pharmacology (ACCP-Pharmacology). Johnson was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014 and has received numerous other awards including teaching awards from both the University of Tennessee (1996) and the University of Florida (2001); the Ohio State University Alumni Association William Oxley Thompson Award for early career achievement (1997), Leon I Goldberg Young Investigator Award from the ASCPT (2004), Paul Dawson Biotechnology Research Award, American Association of Colleges of Pharmacy (AACP) (2007), Therapeutic Frontiers Award (2009) and Russell R Miller Award for Contributions to the Literature (2010), both from ACCP, the Southeastern Universities Research Association Distinguished Scientist Award (2015); AACP Volwiler Research Achievement Award (2016), the ACCP-Pharmacology Distinguished Scientist Award (2019), and ACCP Paul Parker Medal (2019), among others.

Accomplishments:
  • Paul Parker Medal
    2019 · American College of Clinical Pharmacy
  • Distinguished Investigator Award
    2019 · American College of Clinical Pharmacology
  • Volwiler Research Achievement Award
    2016 · American Association of Colleges of Pharmacy
  • Highly Cited Scientist
    2015-2018 · Clarivate Analytics
  • Distinguished Scientist Award
    2015 · Southeastern Universities Research Associate
  • Elected Member
    2014 · National Academy of Medicine
  • Honorary Fellow Award
    2014 · American College of Clinical Pharmacology
  • Russell Miller Award for Contribution to the Literature
    2010 · American College of Clinical Pharmacy
  • Therapeutic Frontiers Award
    2009 · American College of Clinical Pharmacy
  • Fellow
    2009 · American Heart Association; Functional Genomics and Translational Biology Council
  • Paul Dawson Biotechnology Research Award
    2007 · American Association of Colleges of Pharmacy
  • Leon I. Goldberg Young Investigator Award
    2004 · American Society for Clinical Pharmacology and Therapeutics
  • William Oxley Thompson Alumni Award
    1997 · The Ohio State University
  • Fellow
    1996 · American College of Clinical Pharmacy
Publications:
Grants:
  • Jan 2020 ACTIVE
    Personalizing thiazide therapy through clinical and microRNA biomarkers of response to thiazides
    AMER HEART ASSOCIATION · Other
  • Sep 2018 ACTIVE
    Sparking Advancements in Genomic Medicine?
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Jan 2018 ACTIVE
    Training Program for Applied Research and Development in Genomic Medicine
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Jul 2016 – Jun 2018
    A Stem Cell Tactic to Promote Personalized Medicine in Hypertension
    AMER HEART ASSOCIATION · Faculty
  • Jul 2016 – Sep 2020
    A stem cell tactic to promote personalized medicine
    NATL INST OF HLTH NIGMS · Project Manager
  • Oct 2015 – Mar 2019
    OneFlorida Clinical Research Consortium Phase II
    PATIENT-CENTERED OUTCOMES RES INST · Project Manager
  • Jul 2014 – Dec 2015
    Using Different OMICS for the Identification of Novel Biomarkers of Blood Pressure Response to Antihypertensive Drugs
    AMER HEART ASSOCIATION · Principal Investigator
  • Jun 2013 – Sep 2018
    Genomic Medicine Implementation: The Personalized Medicine Program
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Mar 2011 – Feb 2016
    Secondary Prevention of Subcortical Stroke Prevention Genetics Substudy Timing
    NATL INST OF HLTH NINDS · Principal Investigator
  • Aug 2010 – Jul 2017
    Pharmacogenomic Evaluation of Antihypertensive Responses.
    NATL INST OF HLTH NIGMS · Principal Investigator
  • Jul 2007 – Aug 2016
    Clinical and Translational Science Institute
    UF RESEARCH FOU · Project Manager
Patents:
  • Published May 2009
    Use of Genetic Determinants in Cardiovascular Risk Assessment
    #US 2010-0021903-A1
  • Published August 2007
    B-Blocker Pharmacogenetics in Heart Failure
    #US-2008-0269346-A1
  • Published July 2003
    Beta-Adrenoceptor Genetic Polymorphisms and Obesity
    #US-2004-0033524
  • Published February 2002
    Methods of Diagnosing Obesity and Products Related Thereto
    #US-2002-0187491
Education:
  • 1987-1989
    Postdoctoral Fellowship in Pharmacokinetics/Clinical Pharmacology
    The Ohio State University
  • 1987
    Pharm.D.
    The University of Texas at Austin and The University of Texas Health Science Center at San Antonio
  • 1985
    B.S.
    The Ohio State University
Larisa H Cavallari

Larisa H Cavallari Pharm.D., BCPS, FCCP

Associate Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-8245

Dr. Cavallari received her B.S. Pharmacy and Pharm.D. degrees from the University of Georgia. She then completed a Pharmacy Practice Residency at the Veterans Affairs Medical Center in Memphis, Tennessee and a fellowship in Cardiovascular Pharmacogenomics at the University of Florida. Dr. Cavallari accepted a position as an Assistant Professor of Pharmacy Practice at the University of Illinois at Chicago after completing her training and was promoted to Associate Professor in 2009. While at UIC, she directed efforts to implement genotype-guided warfarin dosing for all patients newly starting warfarin during hospitalization. Dr. Cavallari joined the University of Florida Department of Pharmacotherapy and Translational Research as an Associate Professor in April, 2014, where she serves as director of the Center for Pharmacogenomics and Precision Medicine. She also serves as Director of the UF Health Precision Medicine Program. Her research involves discovery and clinical translation of genetic variants related to drug response and has been funded by the NIH, FDA, American Heart Association, and other awards.

Dr. Cavallari has served on both NIH and American Heart Association grant review committees and is a Board Certified Pharmacotherapy Specialist, Fellow of the American College of Clinical Pharmacy, former Chair of the American College of Clinical Pharmacy Research Institute, and Editorial Board Member for the Lexi-Comp pharmacogenetics series.

Accomplishments:
  • Elected Regent
    2019 · American College of Clinical Pharmacy
  • Elected Trustee
    2013-2016 · Research Institute, American College of Clinical Pharmacy
  • Kenneth F. Finger Fellow Alumni Lecturer Award
    2009 · University of Florida
  • Best Paper
    2009 · International Congress on Clinical Pharmacy
  • Fellow
    2008 · American College of Clinical Pharmacy
  • Hans Vahlteich Research Award
    2007 · University of Illinois at Chicago
  • Faculty New Investigator
    2004 · American Association of Colleges of Pharmacy-American Foundation for Pharmaceutical Education Pharmacy
  • Annual Meeting Best Student, Resident, Fellow Paper Award
    2000 · American College of Clinical Pharmacy
  • Kenneth F. Finger Memorial Award for Excellence in Clinical Pharmacy Research
    2000 · University of Florida
  • American Foundation for Pharmaceutical Education for the Biomedical Research Sciences Fellow
    1999-2000 · University of Florida
Publications:
Grants:
  • Aug 2020 ACTIVE
    Identifying Predictors of Spironolactone Response in Patients with Heart Failure with Preserved Ejection Fraction
    NATL INST OF HLTH NHLBI · Other
  • Jul 2020 ACTIVE
    Precision antiplatelet therapy after percutaneous coronary intervention
    NATL INST OF HLTH NHLBI · Principal Investigator
  • Sep 2018 ACTIVE
    Sparking Advancements in Genomic Medicine?
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Apr 2018 – Jul 2019
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Project Manager
  • Apr 2018 – Sep 2019
    Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery
    UF HEALTH SHANDS HOSPITAL · Principal Investigator
  • Jan 2018 ACTIVE
    Training Program for Applied Research and Development in Genomic Medicine
    NATL INST OF HLTH NHGRI · Other
  • Apr 2017 ACTIVE
    OoR CTSI Institutional Matching Support
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Jun 2016 – Oct 2018
    Development and analytic validation of a customized pharmacogenomics panel
    CANON BIOMEDICAL INC · Principal Investigator
  • Sep 2015 – Aug 2016
    2015 Mallinckrodt Research Fellowship Award
    MALLINCKRODT PHARMACEUTICALS · Principal Investigator
  • Sep 2014 – Feb 2019
    Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs
    US FOOD AND DRUG ADMN · Principal Investigator
Michael J Clare-Salzler

Michael J Clare-Salzler M.D.

Professor Emeritus
Department: MD-PATHOLOGY
Phone: (352) 339-3618

Michael J. Clare-Salzler, MD, is a professor of medicine who received his medical degree and internal medicine training from the State University of New York at Buffalo. He began his clinical endocrinology and immunology research career at the University of California in Los Angeles, where he studied the immunopathogenesis of type 1 diabetes. 

Dr. Clare-Salzler maintains an active practice in endocrinology, treating patients with diabetes and other endocrine diseases. 

Certifications:
  • Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine
Specialties:
  • Pathology, Immunology and Laboratory Medicine
Clinical Interests:
  • Diabetes
  • Diabetes – resources
  • Diabetes diet – type 1
  • Diabetes education
  • Pheochromocytoma
  • Thyroid cancer
  • Thyroid diseases
  • Thyroid nodule
  • Type 1 diabetes
  • Type 2 diabetes
Publications:
Grants:
  • Sep 2018 ACTIVE
    A 3D Tissue Map of the Human Lymphatic System
    NATL INST OF HLTH NIAID · Co-Investigator
  • Jun 2018 ACTIVE
    Immune Function and the Progression to Type 1 Diabetes
    NATL INST OF HLTH NIAID · Co-Investigator
  • Jun 2013 – Sep 2018
    Genomic Medicine Implementation: The Personalized Medicine Program
    NATL INST OF HLTH NHGRI · Project Manager
  • May 2013 – Jun 2018
    Immune Function and the Progression to Type 1 Diabetes
    NATL INST OF HLTH NIAID · Project Manager
  • Sep 2012 – Aug 2016
    The JDRF nPOD Viral Work Group: nPOD V
    JDRF · Project Manager
  • Jan 2012 – Mar 2017
    Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery ofInsulin Peptide, Vitamin D3, TGF-b1 and GM-CSF for Type-1 Diabetes
    NATL INST OF HLTH · Project Manager
  • Jan 2010 ACTIVE
    UFFChandler Stetson Professorship Experimental Pathology
    UF FOU · Principal Investigator
  • Jul 2006 – Dec 2020
    21st Century Research & Economic Development Investment Program (REDIP)
    STATE UNIV SYS OF FL BOARD OF GOVERNORS · Project Manager
Patents:
  • Issued July 2018
    Antigen-Specific, Tolerance-Inducing Microparticles and Uses Thereof
    #10,016,371
  • Published July 2018
    Particle-Based Vaccine for Induction of Specific Tolerance (CON 13603)
    #US-2018-0303760-A1
  • Published July 2009
    Materials and Methods For The Detection, Prevention and Treatment of Autoimmune Disease
    #US-2010-0178652-A1
  • Issued October 2005
    Materials And Methods For Detection And Treatment Of Immune System Dysfunctions (DIV)
    #6,953,578
  • Published August 2003
    Cox-2 Mediated Altered Prostaglandin Balance in Diabetes Complications
    #US-2004-0121489-A1
  • Published April 2003
    Methods and Compositions for Expressing a Nucleic Acid in a Dendritic Cell
    #US-2004-0072351-A1
  • Issued April 2001
    Materials And Methods For Detection And Treatment Of Immune System Dysfunction (DIV)
    #6,218,133
  • Issued January 2001
    Materials And Methods For Detection And Treatment Of Immune System Dysfunctions
    #6,168,792
  • Issued August 1999
    Materials and Methods for Detection and Treatment of Immune System Dysfunctions.
    #5,939,069
Education:
  • 1988
    Other Program – Endocrinology, Diabetes and Metabolism
    University of California, Los Angeles
  • 1982
    Residency – Internal Medicine
    State University of New York
  • 1980
    Internship- Internal Medicine
    State University of New York
  • 1979
    Medical Degree
    SUNY at Buffalo
Rhonda M Cooper-DeHoff

Rhonda M Cooper-DeHoff Pharm.D., M.S., FAHA, FACC, FCCP

Associate Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-6184

Dr. Cooper-DeHoff is a Associate Professor in the Department of Pharmacotherapy and Translational Research, and the Department of Pharmaceutics in the College of Pharmacy, and in the Division of Cardiovascular Medicine, College of Medicine at the University of Florida.

Accomplishments:
  • Fellow
    2014 · American College of Clinical Pharmacy
  • Research Featured
    2009 · American Society of Hypertension
  • Clinical Science Award
    2008 · Consortium for Southeastern Hypertension Control
  • Fellow
    2007 · American Heart Association
Research Summary:

Dr. Cooper-DeHoff’s research interests include hypertension, metabolic syndrome, diabetes, coronary artery disease and antihypertensive drug-induced diabetes, as well as the impact of pharmacogenetic variations in each of these areas. She’s also the lead investigator of the hypertension working group within the Patient-Centered Outcomes Research Institute-funded Clinical Data Research Network — OneFlorida — which affords trainees the opportunity to work at an epidemiologic level to explore population-level questions about hypertension. Trainees also learn about the complexities and benefits of working in electronic health record data at the research level. Dr. Cooper-DeHoff’s resistant hypertension research includes mass spectrometry analysis of antihypertensive drugs, metabolomics and gut microbiota available for analysis.

Publications:
Grants:
  • Apr 2020 ACTIVE
    Use of Real-World Evidence to Characterize Patients with Uncontrolled Hypertension
    YALE UNIV · Co-Investigator
  • Nov 2018 – Nov 2019
    Cardiovascular Health Collaborative Research Group
    PATIENT-CENTERED OUTCOMES RES INST · Principal Investigator
  • Sep 2018 ACTIVE
    Using PCORnet to Compare Blood Pressure Control Strategies
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jul 2018 ACTIVE
    Advancing Personalized Hypertension Care through Big Data Science
    NATL INST OF HLTH NHLBI · Other
  • Jun 2018 ACTIVE
    INTEGRATIVE DATA APPROCACHES FOR RESISTANT HYPERTENSION IDENTIFICATION AND PREDICTION
    NATL INST OF HLTH NHLBI · Other
  • Sep 2017 ACTIVE
    Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
    US ARMY MED RES ACQUISITION · Co-Investigator
  • Jan 2017 – Aug 2018
    PCORnet Cardiovascular Health Collaborative Research Group
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Oct 2015 – Mar 2019
    OneFlorida Clinical Research Consortium Phase II
    PATIENT-CENTERED OUTCOMES RES INST · Project Manager
  • May 2015 – Apr 2016
    Optimizing Rural Health Clinic Infrastructure to Maximize BP Control (OPTI-BP)
    FL HLTH EQUITY RESEARCH INST · Principal Investigator
  • Apr 2015 – Dec 2020
    Clinical and Translational Science Institute (CTSI)
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Aug 2010 – Jul 2017
    Pharmacogenomic Evaluation of Antihypertensive Responses.
    NATL INST OF HLTH NIGMS · Co-Investigator
  • Jul 2007 – Aug 2016
    Clinical and Translational Science Institute
    UF RESEARCH FOU · Project Manager
Patents:
  • Published April 2004
    Combination Drug Therapy for Treating Hypertension
    #US 2005-0032784 A1
  • Issued November 1999
    Method & System For Interactive Prescription and Distribution of Perscriptions in Conducting Medical Studies (CON)
    #5,991,731
Education:
  • 2007
    M.S.
    University of Florida
  • 1986
    Pharm.D.
    University of California at San Fransisco
Julio Duarte

Julio Duarte Pharm.D., Ph.D.

Assistant Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-8132

Julio Duarte received his Pharm.D. and Ph.D. degrees from the University of Florida. After completing training, he became an assistant professor of pharmacy practice at the University of Illinois at Chicago where he served for over four years. While there, Dr. Duarte became the director of the pharmacogenomics laboratory, and also co-director of the University of Illinois Hospital Personalized Medicine Program. In late 2015, he returned to the University of Florida as an assistant professor within the department of pharmacotherapy and translational research. Dr. Duarte’s research interests include the biological mechanisms behind both disease development and drug response in heart failure and pulmonary hypertension. His NIH-funded laboratory conducts translational research, attempting to discover genomic predictors of drug response, as well as using genomics to identify novel targets for future drug development. He has served on U.S Department of Defense grant review committees and is also an active member of the Council for Functional Genomics and Translational Biology within the American Heart Association.

Accomplishments:
  • Outstanding Clinical Research Award
    2017 · University of Florida College of Pharmacy
  • Fellow
    2017 · American Heart Association
  • Hans Vahlteich Research Scholar
    2013 · College of Pharmacy, University of Illinois at Chicago
Publications:
Grants:
  • Nov 2015 – Mar 2020
    Improving treatment personalization for pulmonary hypertension associated with diastolic heart failure
    NATL INST OF HLTH NIGMS · Principal Investigator
Education:
  • 2010
    Ph.D.
    University of Florida
  • 2006
    Pharm.D.
    University of Florida
Jatinder Lamba

Jatinder Lamba Ph.D., M.Sc.

Professor And Graduate Coordinator
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-6425

Dr. Jatinder Lamba is currently Professor in the Department of Pharmacotherapy and Translational Research. She did her post-doctoral training at St. Jude Children’s Research Hospital in Memphis, Tennessee. Prior to joining University of Florida, she was an Associate Professor at University of Minnesota, Department of Experimental and Clinical Pharmacology, College of Pharmacy and the Director of the Pathway driven Pharmacogenomics; University of Minnesota Alliance (PUMA) Institute of Personalized Medicine.

Dr Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials. The long-term goal of her research is to move pharmacogenetic testing into the clinical setting to improve safety and efficacy of drug therapy. Dr. Lamba’s research on pharmacogenomics of anti-leukemic agents has been funded by NIH/NCI since 2008. Specifically, her current NCI funded R01 focuses on pharmacogenomics/ epigenomics of cytarabine (ara-C), a nucleoside analog that is the backbone of anti-leukemia chemotherapy in pediatric AML patients. Her group is working on developing algorithms to incorporate pharmacogenomics/epigenomic markers with other prognostic factors to advance precision medicine in oncology. Identification of such patients upfront will provide opportunity to tailor the initial chemotherapy to achieve maximum benefit.

Dr. Lamba’s lab is the first one to identify genetic polymorphisms in CD33 gene that are predictive of response to CD33 targeted agents in AML. These results hold promise in utilizing preemptive genotype to select patients most likely to benefit from CD33-directed therapy such as gemtuzumab ozogamicin in treating AML. Previous work on CD33 genomics was funded by NCI and more in-depth characterization of CD33 as AML therapeutic target is funded by a recent award from leukemia Lymphoma Society.

Given a critical gap of our understanding in metabolic dysregulation in AML, Dr. Lamba’s group is focused understanding the metabolomics differences and biomarkers of prognostic significance in pediatric AML. Dr. Lamba’s recent work is focused towards utilizing transcriptomics to build and refine leukemic stem cell signatures and AML drug response signatures of prognostic and predictive value in AML.

Dr. Lamba has served as chair of Pharmacogenomics SIG at AACP (2013) and is currently vice-chair of Pharmacogenomics focus group with AAPS. She has served as a grant reviewer for numerous NIH study sections and has reviewed grants for international agencies as Italian Ministry of Health. She has published more than 90 research articles in peer-reviewed journals and is on the editorial boards of Leukemia and Lymphoma, Pharmacogenomics and Frontiers in Pharmacogenomics and genomics, JCMM. Dr. Lamba is currently Professor in College of Pharmacy and is also Graduate Program coordinator for PTR department. Dr. Lamba is very committed towards training of future generation of scientist. She has trained 6 Ph. D students, 5 Post-doctoral fellows several Pharm D students and 3 hematology-oncology fellows and several under-graduate students including minority and underrepresented students.

Publications:
Grants:
  • Sep 2020 ACTIVE
    Pharmacogenomic Drivers of Efficacy in Anti-CD33 Immunotherapeutic Treatment Strategies
    AMER FOU FOR PHARM EDU · Other
  • Sep 2020 ACTIVE
    AFPE Fellowship: Rho Chi -AFPE Graduate Fellowship
    AMER FOU FOR PHARM EDU · Other
  • Aug 2020 ACTIVE
    Pharmacokinetics and Pharmacogenomics of Pediatric Chemotherapeutics
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jan 2020 ACTIVE
    Asparaginase Premedication, Hypersensitivity, and Therapeutic Drug Monitoring in Pediatric Patients with Acute Lymphoblastic Leukemia or Lymphoma
    CHILDRENS HOSP OF ORANGE COUNTY · Principal Investigator
  • Jul 2019 – Jun 2020
    Personalizing CD33-directed immunotherapy for pediatric AML
    CHILDRENS ONCOLOGY GROUP · Principal Investigator
  • Jul 2019 ACTIVE
    Personalizing CD33-directed Immunotherapy for Pediatric AML
    LEUKEMIA & LYMPHOMA SOC · Principal Investigator
  • Apr 2019 ACTIVE
    Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT Recipients
    FL DEPT OF HLTH LIVE LIKE BELLA · Principal Investigator
  • Jun 2018 ACTIVE
    OR-DRPD-ROD2018: Development of Leukemia-Oncotype Prototype CARS (Cytarabine AML Response Score) for Prediction of Relapse Risk in AML
    UF RESEARCH · Principal Investigator
  • Feb 2018 – Jan 2019
    Impact of CD33 Genetics on Clinical Outcome in Pediatric AML Patients Treated on AAML0531 Clinical Trial
    CHILDRENS ONCOLOGY GROUP · Principal Investigator
  • Dec 2016 – Jan 2020
    Multiple Sponsors
    MULTIPLE SPONSORS · Principal Investigator
  • Jan 2015 – Jan 2016
    DNA ISOLATION/GENOTYPING COLLABORATION
    UNIV OF MINNESOTA · Principal Investigator
  • Sep 2014 – Apr 2020
    Pharmacogenomics of Ara-C in AML
    NATL INST OF HLTH NCI · Principal Investigator
  • Jul 2014 – Dec 2015
    Impact of genetic variation on response to GO therapy in COG-AML clinical trials
    NATL INST OF HLTH NCI · Principal Investigator
Education:
  • 2000
    Ph.D.
    Postgraduate Institute of Medical Education and Research
  • 1994
    M.Sc.
    Postgraduate Institute of Medical Education and Research
  • 1992
    B.Sc.
    Panjab University
David R Nelson

David R Nelson M.D.

Senior Vice President For Health Affairs, UF & President, UF Health
Department: Senior Vice President for Health Affairs
Phone: (352) 733-1700

David R. Nelson, M.D., was appointed senior vice president for health affairs at the University of Florida and president of UF Health in April 2019. Dr. Nelson oversees operations for all components of UF Health, the university’s academic health center, with campuses in Gainesville and Jacksonville. This includes six health science colleges, nine interdisciplinary research centers, three hospital systems and more than 100 physician practices. He is committed to strategically position UF Health for smart growth; enhancing operations; supporting faculty, staff and students; and fostering a diverse, inclusive and equitable community. He also has continued to explore ways to optimize the speed of translation of research, bringing science to the bedside and to the community to improve patient care for individuals and populations. A professor of medicine and an expert in liver disease, Dr. Nelson’s record of academic achievement includes more than $100 million in research funding, more than 200 publications and multiple leadership roles in his area of expertise. He has co-authored the U.S. treatment guidelines for hepatitis C, the Clinical Pharmacogenetics Implementation Consortium guidelines for the use of genomic-guided hepatitis C (HCV) therapy, and represented the United States on the World Health Organization HCV guidelines committee. As a principal investigator on basic science, translational research and training grants, he developed an international real world data network (HCV-TARGET), a collaboration between clinician investigators, the pharmaceutical industry and the Food and Drug Administration (FDA). This transformed drug development pathways and led to faster and safer development of HCV therapies, resulting in his recognition by the FDA with the Regulatory Science Excellence Honor in 2018. In 2013, he was recognized for one of the Clinical Research Forum’s Top 10 Clinical Research Achievements and in 2014, he received the Association of American Medical Colleges’ Learning Health System Research Champion Award. He has continuously been recognized as one of America’s top physicians/gastroenterologists and has been the recipient of multiple exemplary teaching awards, an outstanding alumnus award from his medical school, a UF Research Foundation Professorship Award and a UF Term Professorship Award.

Dr. Nelson received his undergraduate degree from Dartmouth College and his medical degree from State University of New York Upstate University in Syracuse, New York. He completed a residency in internal medicine at the University of Massachusetts and obtained fellowship training in gastroenterology and hepatology at UF.

Certifications:
  • Gastroenterology
    American Board of Gastroenterology
  • Internal Medicine
    American Board of Internal Medicine
  • Transplant Hepatology
    American Board of Internal Medicine
Specialties:
  • Medicine
Subspecialties:
  • Gastroenterology
  • Transplant Hepatology
Clinical Interests:
  • Cirrhosis
  • Hepatitis C
  • Liver cancer – hepatocellular carcinoma
  • Liver disease
  • Liver disease – resources
  • Liver transplant
Publications:
Grants:
  • Sep 2018 ACTIVE
    Sparking Advancements in Genomic Medicine?
    NATL INST OF HLTH NHGRI · Co-Investigator
  • May 2018 ACTIVE
    Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
    NATL INST OF HLTH NIDA · Other
  • Apr 2018 – Oct 2018
    Stakeholder Engagement and Multi-Risk Assessment in Dental Care Settings
    UNIV OF ALABAMA BIRMINGHAM · Co-Investigator
  • Apr 2018 – Jul 2019
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Principal Investigator
  • Nov 2017 – Oct 2018
    Safety of Direct Acting Antiviral Medications for Hepatitis C
    KAISER FOU RESEARCH INSTITUTE · Co-Investigator
  • Apr 2017 ACTIVE
    HSC COM Matching Commitment
    UNIV OF FLORIDA · Principal Investigator
  • Apr 2017 ACTIVE
    OoR CTSI Institutional Matching Support
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Apr 2017 – Jun 2020
    COM CTSI Institutional Matching Support Year 3-4
    FL CLINICAL PRACTICE ASSO · Principal Investigator
  • Apr 2017 – Mar 2018
    The National Dental PBRN FY18
    UNIV OF ALABAMA BIRMINGHAM · Co-Investigator
  • Apr 2017 – Mar 2018
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Principal Investigator
  • Mar 2017 ACTIVE
    A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
    ABBVIE · Principal Investigator
  • Aug 2016 – Jul 2017
    The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)
    UNIV OF NORTH CAROLINA · Principal Investigator
  • Jul 2016 ACTIVE
    Collaborating to Advance Teaching and Learning of Science Educators and Students (CATALySES)
    NATL INST OF HLTH NIGMS · Co-Investigator
  • Apr 2016 – Mar 2017
    TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TO IMPROVE HEALTH ,
    NATL INST OF HLTH NCATS · Principal Investigator
  • Apr 2016 – Mar 2017
    TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TOIMPROVE HEALTH
    NATL INST OF HLTH NCATS · Project Manager
  • Jan 2016 – Apr 2017
    The National Dental PBRN
    UNIV OF ALABAMA BIRMINGHAM · Project Manager
  • Jan 2016 ACTIVE
    Prioritize Study
    PATIENT-CENTERED OUTCOMES RES INST · Principal Investigator
  • Sep 2015 – Sep 2018
    An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Subjects with Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)
    ABBVIE · Principal Investigator
  • Aug 2015 – Jul 2018
    Patient Reported Outcomes Project of HCV-Target (Prop up TARGET)
    UNIV OF NORTH CAROLINA · Principal Investigator
  • Aug 2015 – Jul 2016
    Validation of an Observer Reported Outcome (ObsRO) Measure of Home Functionality in Children with Pyruvate Dehydrogenase Complex Deficiency (PDCD)
    UNITED MITOCHONDRIAL DISEASE FOU · Project Manager
  • Jul 2015 ACTIVE
    Florida Academic Cancer Center Alliance Seed Grants
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Jun 2015 – Jun 2023
    A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials"
    GILEAD SCIENCES · Principal Investigator
  • Jun 2015 – Dec 2016
    Evaluation of Baseline HCV Resistance mutations in Genotype1 patients initiating tretamnent in real-world settings
    JANSSEN SERVICES · Principal Investigator
  • May 2015 – Mar 2016
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Principal Investigator
  • May 2015 – Mar 2016
    UF CTSI NRSA Training Core
    NATL INST OF HLTH · Project Manager
  • Apr 2015 – Dec 2020
    Clinical and Translational Science Institute (CTSI)
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Feb 2015 – Feb 2018
    A single arm, open label study to evaluate the efficacy and satety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1,2,4,5 or 6 infection and compensated Cirrhosis
    ABBVIE · Principal Investigator
  • Jul 2014 – Oct 2017
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Jun 2014 – Sep 2018
    BMS AI444-257 A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Mar 2014 ACTIVE
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    GILEAD SCIENCES · Principal Investigator
  • Feb 2014 – Feb 2017
    MK-5172 'A PHASE II/II RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH HCV AND CHRONIC KIDNEY DISEASE'
    Merck Sharp & Dohme · Principal Investigator
  • Feb 2014 – Feb 2017
    IDX-03YF '3-YEAR, Observ Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, DAA'
    IDENIX PHARMACEUTICALS · Principal Investigator
  • Feb 2014 – Feb 2016
    AI444-218 'A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Na?ve and Treatment Experienced Subjects with Genotype 3 Chronic Hepatitis C Infection'
    BRISTOL MYERS SQUIBB CO PHARM RES INST · Principal Investigator
  • Dec 2013 – Dec 2016
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    JANSSEN SERVICES · Principal Investigator
  • Oct 2013 – Dec 2020
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    ABBVIE · Principal Investigator
  • Oct 2013 – Oct 2016
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
    NOVARTIS PHARMA AG · Principal Investigator
  • Oct 2013 – Oct 2016
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    ROCHE MOLECULAR SYSTEMS · Principal Investigator
  • Sep 2013 – Sep 2016
    AbbVie M13-102 'A Follow-up Study to Assess Resistance and Durability of Response to AbbVie DAA Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the TX of Chronic HCV Infection' (AbbVie Protocol M13-102)
    ABBVIE · Principal Investigator
  • Jul 2013 – Dec 2019
    Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
    US ARMY MED RES ACQUISITION · Project Manager
  • Jun 2013 – Sep 2018
    Genomic Medicine Implementation: The Personalized Medicine Program
    NATL INST OF HLTH NHGRI · Project Manager
  • Apr 2013 – Mar 2016
    GS-US-337-0108 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir FDC ? RBV for 8 Wks and Sofosbuvir/Ledipasvir FDC Combo for 12 Wks in Tx-Na?ve Subjects with Chronic Genotype 1 HCV'
    GILEAD SCIENCES · Principal Investigator
  • Apr 2013 – Apr 2016
    A Randomized Study to Evaluate the Safety and Efficacy of IDX179 in Combination with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection'
    IDENIX PHARMACEUTICALS · Principal Investigator
  • Jan 2013 – Jan 2016
    BI 201335 and BI 207127 Combination Therapy in Treatment -Naive HCV Patients
    BOEHRINGER INGELHEIM PHARM INC · Principal Investigator
  • Dec 2012 – Dec 2015
    GS-US-337-0109 'G??A Phase 3, Multicenter, Randomized, Open-Label Study for Efficacy and Safety of Sofosbuvir/GS-5885 FDC -? Ribavirin for 12 & 24 Weeks in Treatment-Experienced Subjects w/Chronic Genotype 1 HCV InfectionG??
    GILEAD SCIENCES · Principal Investigator
  • Nov 2012 – Nov 2015
    Nelson Abbott M13-099 'A Randomized, Open-label Study of ABT 450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 W RBV in Geno 1 (HCV) Infection and Human Cirrhosis (TURQUOISE-II)'
    ABBVIE · Principal Investigator
  • Oct 2012 – Oct 2015
    Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
    ABBVIE · Principal Investigator
  • Oct 2012 – Dec 2019
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
    Merck Sharp & Dohme · Principal Investigator
  • Sep 2012 – Sep 2015
    GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
    GILEAD SCIENCES · Principal Investigator
  • Mar 2012 – Mar 2016
    An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
    ABBOTT LABORATORIES · Principal Investigator
  • Nov 2011 – Sep 2018
    GS-US-248-0123 A Long Term Follow-up Registry Study of Subjects Who DidNot Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
    GILEAD SCIENCES · Principal Investigator
  • Nov 2011 – Nov 2019
    GS-US-248-0122, A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
    GILEAD SCIENCES · Principal Investigator
  • Nov 2011 – Nov 2017
    'A PHASE 3B STUDY OF 2 TX DURATIONS OF TELAPREVIR, PEGASYS, AND COPEGUS IN TREATMENT-NAIVE AND PRIOR RELAPSER SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND IL28B CC GENOTYPE'
    VERTEX PHARMACEUTICALS · Principal Investigator
  • Oct 2011 ACTIVE
    HCV-TARGET Primary Operating Project with subprojects
    UF DIV OF SPONSORED RESEARCH · Principal Investigator
  • Sep 2011 ACTIVE
    HCV TARGET: Hepatitis C Therapeutic Registry and ResearchNetwork
    KADMON · Principal Investigator
  • Sep 2011 – Sep 2017
    M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
    ABBVIE · Principal Investigator
  • Jun 2011 – Jun 2017
    'Parallel-Open-Label, Rand Study to Eval. Safety, Pharmacokinetics and Pharmacodynamics of PSI-7977 in Combination with BMS-790052 with or without Ribavirin in Treatment-Naive Subjects Chronically Infected with Hepatitis C Virus Genotypes 1, 2 OR 3
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Dec 2010 – Dec 2016
    GS-US-196-0123
    GILEAD SCIENCES · Principal Investigator
  • Aug 2010 – Aug 2016
    BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Mar 2010 – Mar 2016
    VX09-222-103 'A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Trea
    VERTEX PHARMACEUTICALS · Principal Investigator
  • Jul 2007 – Aug 2016
    Clinical and Translational Science Institute
    UF RESEARCH FOU · Principal Investigator
  • Jul 2006 – Dec 2020
    21st Century Research & Economic Development Investment Program (REDIP)
    STATE UNIV SYS OF FL BOARD OF GOVERNORS · Project Manager
  • Mar 2005 – Feb 2020
    Lawton Family Liver Research – UFF Fund #008386
    UF FOU · Principal Investigator
  • Mar 2005 – Feb 2020
    Res & Dev Gastroenterology – UFF Fund #002739
    UF FOU · Principal Investigator
Education:
  • 1996
    Fellowship – Gastroenterology
    University of Florida
  • 1993
    Residency – Internal Medicine
    University of Massachusetts
  • 1990
    Medical Degree
    SUNY Health Science Center
Danxin Wang

Danxin Wang M.D., Ph.D.

Associate Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-7673

Dr. Wang received her MD degree from Fudan University Medical School and her Ph.D from the Academy of Military Medical Science in Beijing. She did postdoctoral training at the University of California San Francisco. She was a Research Assistant Professor at Ohio State University, Department of Cancer Biology and Genetics and Associate Director of Center for Pharmacogenomics prior to joining the University of Florida.

Dr. Wang’s research interests are the discovery of genetic biomarkers for personalized drug therapy. She has discovered many functional regulatory variants in genes related to drug therapy in the areas of cardiovascular diseases, mental diseases and drug dependence. Some of these functional variants are currently included in biomarker testing panels to predict drug response.

Funded by NIH R01 award, “Expression genetics of CYP3A drug metabolizing enzymes”, Dr. Wang’s current research is to understand factors controlling the expression of CYP3A, the main drug metabolizing enzyme in the liver. Using recently developed cutting edge functional genetics/genomics approaches, the research will focus on understanding what genetic, epigenetic and non-genetic factors may contribute to CYP3A variability, with the goal to identify biomarker predicting CYP3A enzyme activity for personalized therapy of nearly 50% of currently used medications.

Dr. Wang has served as an Associate Editor of “European Journal of Pharmaceutical Sciences” and was on editorial Board of “Journal of Pharmacogenomics and Pharmacoproteomics”. She has also served as grant reviewer for NIH.

Grants:
  • May 2018 ACTIVE
    Genetic determinants of ACEI prodrug activation
    UNIV OF MICHIGAN · Principal Investigator
  • May 2018 ACTIVE
    Expression Genetics of CYP3A Drug Metabolizing Enzymes
    NATL INST OF HLTH NIGMS · Principal Investigator
  • May 2018 ACTIVE
    Translational candidate-gene studies of simvastatin-induced myopathy in African Americans
    OHIO STATE UNIV · Principal Investigator
Education:
  • 1999
    Ph.D.
    Academy of Military Medical Sciences
  • 1988
    M.S.
    Fudan University Medical School
  • 1985
    M.D.
    Fudan University Medical School
Awewura Kwara

Awewura Kwara MD, MB, ChB, MPH, TM

Professor Of Medicine
Department: MD-INFECTIOUS DISEASES
Phone: (352) 273-9501

Dr. Kwara is a professor of medicine within the Division of Infectious Diseases & Global Medicine. He is an Infectious Diseases Specialist with broad expertise in general infectious diseases, HIV/AIDS and travel medicine. He received his medical degree from the University of Ghana Medical School and master’s in public health and tropical medicine degree from Tulane University. Dr. Kwara completed Internal Medicine Residency at Cook County Hospital in Chicago and an Infectious Disease Fellowship at Tulane University Health Sciences Center in New Orleans. He is board certified in internal medicine and infectious diseases. He is also certified in Clinical Tropical Medicine and Travelers’ Health.

Certifications:
  • Infectious Disease
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine
Specialties:
  • Medicine
Subspecialties:
  • Infectious Disease
Clinical Interests:
  • HIV/AIDS
  • Infectious diseases
  • Traveler’s guide to avoiding infectious diseases
Research Summary:

Dr. Kwara’s research is focused on clinical pharmacology of antiretroviral and antituberculosis therapy in persons living with human immunodeficiency virus (HIV) with tuberculosis (TB) or hepatitis B virus (HBV) coinfection. He is the PI of NIH that seeks to investigate the pharmacokinetics, drug-drug interactions and pharmacogenetic determinants of HIV, HBV and TB treatment outcomes. His work with collaborators in the US and Ghana seeks to unravel the molecular basis for the inter-individual variability in TB, HBV and HIV drugs pharmacokinetics, and drug-drug interactions in individuals with HIV and TB coinfection. Dr. Kwara collaborates with colleagues at the Center for Pharmacogenenomics in the Department of Pharmacotherapy and Translation Research at UF College of Pharmacy. Beyond the field of HIV therapeutics, our research could inform how pharmacogenomics and/or applied pharmacokinetics can be used to optimize the treatment outcome of common infectious diseases at the individual and population levels.

Research Interests:
  • HIV
  • HIV/HBV coinfection
  • Pharmacogenomics
  • TB/HIV coinfection
  • Translational and clinical pharmacology
  • Tuberculosis
Publications:
Grants:
  • Dec 2020 ACTIVE
    Pharmacokinetics and Pharmacodynamics of Dolutegravir in Children Weighing =20 Kg Living with HIV with and without TB Coinfection
    NATL INST OF HLTH NIAID · Principal Investigator
  • Apr 2020 ACTIVE
    Adherence and Intracellular Pharmacology of Tenofovir and HBV Suppression in People with HBV/HIV Coinfection
    NATL INST OF HLTH NIAID · Principal Investigator
  • Sep 2018 ACTIVE
    Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
    NATL INST OF HLTH NICHD · Principal Investigator
  • Jun 2016 – Aug 2018
    Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
    NATL INST OF HLTH NICHD · Principal Investigator
  • Jun 2016 ACTIVE
    Training Program in Tuberculosis and HIV Research in Ghana D43
    FOGARTY INTERNATIONAL CENTER · Principal Investigator
Education:
  • 2001
    Fellowship – Infectious Disease
    Tulane University
  • 1999
    Residency – Internal Medicine
    Cook County Hospital
  • 1997
    Internship – Internal Medicine
    Cook County Hospital
  • 1992
    Bachelor of Medicine and Bachelor of Surgery
    University of Ghana

Cancer Genomics

Thomas J George, Jr

Thomas J George, Jr M.D., F.A.C.P.

Professor
Department: MD-HEMATOLOGY/ONCOLOGY
Phone: (352) 273-7832

Dr. George is a clinical investigator and educator with a focus on gastrointestinal malignancies. As director of the GI Oncology Program at the University of Florida, Dr. George helps to oversee the treatment of all patients with GI malignancies. He previously served as chair of the Medical Advisory Board to the State of Florida Department of Health and the Screen for Life Colorectal Cancer Screening Program, which targets historically underserved populations. He also recently completed a 10 year term as the gubernatorial-appointed chair of the Florida Cancer Control and Research Advisory Council, which advises the legislature, Department of Health, and state surgeon general on all cancer related matters and policy. He currently serves as the Associate Director for Clinical Research at the UF Health Cancer Center. Through participation with large oncology clinical trial cooperative groups and the National Cancer Institute, Dr. George is an active clinician and clinical investigator in GI malignancies and early phase clinical trials testing new therapies for patients with advanced cancers. He is a member of the medical honor society Alpha Omega Alpha, the American Society of Clinical Oncology, and numerous cancer research groups.

Accomplishments:
  • University of Florida Term Professor Award
    2018-2019 · University of Florida
  • Exemplary Mentor Award
    2017 · University of Florida
  • Most Valuable Player Award
    2013 · UF Health Cancer Center
  • Master Clinician
    2013 · UF Department of Medicine
  • Exemplary Teacher
    2011 · University of Florida
  • Excellence in Research Award
    2010 · University of Florida
  • Exemplary Teacher
    2010 · University of Florida
  • Excellence in Teaching (Resident/Fellows)
    2009 · University of Florida
  • Exemplary Teacher
    2008 · University of Florida
  • Excellence in Research Award
    2008 · University of Florida
  • Fellow
    2007 · American College of Physicians
  • Excellence in Teaching (Medical Students)
    2007 · University of Florida
  • Excellence in Teaching (Fellows)
    2007 · University of Florida
Certifications:
  • Hematology
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine
  • Oncology
    American Board of Internal Medicine
Specialties:
  • Medicine
Subspecialties:
  • Hematology and Oncology
  • Oncology
Clinical Interests:
  • Cancer treatment information
  • Colon cancer screening
  • Colorectal cancer
  • Colorectal cancer – resources
  • Esophageal cancer
  • Liver metastases
  • Pancreatic cancer
  • Stomach cancer
Research Summary:

Clinical research in gastrointestinal malignancies is a primary aspect of Dr. George’s academic interests.  Specific areas of focus include active participation and development of clinical trials to promote novel drug application in patient care, quality of life/cancer care decision making, and identification of predictive markers for individualized therapy.  He has been a 10 year Gubernatorial appointee to the Executive Committee and immediate past Chair of the Florida Cancer Control and Research and Advisory Council which advises the legislature on matters related to cancer care and research in the state. He is a dedicated mentor and teacher of fellows, residents, and students in the College of Medicine and junior faculty both at UF and other major institutions.

Experimental Therapeutics – Dr. George is involved as a Principle Investigator in numerous clinical trials aimed at determining the optimal treatment for patients with gastrointestinal malignancies and bringing new therapies to patients with advanced cancers.  Collaboration includes numerous national clinical trial groups as well as the National Cancer Institute.  Representative protocols include studies in colon, rectal, pancreatic, esophagogastric, hepatobiliary and other treatment refractory cancers.  These novel therapies offer patients access to new treatments and hold the promise of becoming the next breakthrough in cancer patient care. 

Personalized Oncology – As cancer care becomes more complex, focus on a tailored approach to individualized treatments which maximize benefit while minimizing risk is critical.  Research involving the identification of specific markers or elements of a patient or their cancer which will predict, in advance, response to a given therapy is an area of active investigation.  The incorporation of new molecular markers, gene expression profiling, and pharmacogenomics into clinical care will help to provide patients with truly personalized care. 

Quality of Life and Decision Making – Patients and their loved ones facing the new diagnosis of a cancer face a variety of potentially overwhelming treatment options and decisions.  Collaboration with behavioral scientists, communication experts, and others are helping to break down the complex process of decision making in an attempt to determine how best to deliver treatment options and maximize quality of life.

Educating the Next Generation of Oncologists – The next generation holds the keys to continuing the work currently ongoing in cancer biology, therapeutics, and patient care.  Cancer therapies and knowledge are constantly changing and medicine requires a lifelong commitment to education. Development of novel educational tools, training modules, and advanced curricula aimed at providing oncologists with the skills needed to practice state of the art medicine while maintaining the humanism and sensitivity required for being entrusted with the honor of caring for patients with cancer is an area of ongoing professional and research interest.

Publications:
Grants:
  • Jul 2020 ACTIVE
    Colorectal cancer (CRC)
    UF FOU · Principal Investigator
  • Jun 2020 ACTIVE
    Pancreatic Cancer Action Network Precision Promise Clinical Trial Consortium Sites
    Pancreatic Cancer Action Network · Principal Investigator
  • Mar 2020 ACTIVE
    VICKtOrY Early Clinical Trials Consortium
    YALE UNIV · Principal Investigator
  • Mar 2020 ACTIVE
    NRG Oncology Network Group Operations Center
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Jan 2020 ACTIVE
    Extracting information from clinical narratives for Clinical Outcomes Research
    PATIENT-CENTERED OUTCOMES RES INST · Co-Investigator
  • Dec 2019 ACTIVE
    Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
    NRG ONCOLOGY FOU · Principal Investigator
  • Sep 2019 ACTIVE
    Testing novel drug combination for pancreatic cancer
    FL DEPT OF HLTH BIOMED RES PGM/J&E KING · Co-Investigator
  • Mar 2019 ACTIVE
    A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    Molecular Analysis for Therapy Choice (MATCH)
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS)
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    NRG Oncology Network Group Operations Center
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 – Feb 2020
    NRG Oncology Network Group Operations Center
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Mar 2019 – Feb 2020
    FDP Research Subaward Agreement- Amendment 1
    UNIV OF PITTSBURGH · Principal Investigator
  • Jan 2019 ACTIVE
    Systematic Analysis of Clinical Study Generalizability Assessment Methods with Informatics
    FL STATE UNIV · Co-Investigator
  • Sep 2018 – Feb 2019
    ET-CTN with Phase 2 Emphasis
    UNIV OF PITTSBURGH · Principal Investigator
  • Mar 2018 – Feb 2019
    Integrated Translational Genoproteomics Center at Washington University
    WASHINGTON UNIV · Principal Investigator
  • Jan 2018 ACTIVE
    Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient
    NRG ONCOLOGY FOU · Principal Investigator
  • Jan 2018 ACTIVE
    Training Program for Applied Research and Development in Genomic Medicine
    NATL INST OF HLTH NHGRI · Other
  • Mar 2017 – Feb 2019
    NRG Oncology Network Group Operations Center – NRG-GI002
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2017 – Feb 2018
    Integrated Translational Genoproteomics Center at Washington University
    WASHINGTON UNIV · Principal Investigator
  • Feb 2017 ACTIVE
    A patient-centered intervention using virtual technology to reduce colorectal cancer disparities in primary care
    NATL INST OF HLTH NCI · Co-Investigator
  • Jan 2017 ACTIVE
    A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
    NRG ONCOLOGY FOU · Principal Investigator
  • Jan 2017 ACTIVE
    DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    NRG ONCOLOGY FOU · Principal Investigator
  • Dec 2016 – Jun 2020
    F020991 – Colorectal Cancer Screening Project
    UF FOU · Principal Investigator
  • Oct 2016 ACTIVE
    NRG Affiliate Master-Federal
    NRG ONCOLOGY FOU · Principal Investigator
  • Jul 2016 – Jun 2017
    Leading Innovation for Transformation (LIFT) Organized Approaches to Colorectal Cancer Screening FY17
    FL DEPT OF HLTH · Co-Investigator
  • May 2016 – May 2021
    A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Mar 2016 – Feb 2019
    INTEGRATED TRANSLATIONAL GENOPROTEOMICS CENTER AT WASHINGTON UNIVERSITY
    WASHINGTON UNIV · Principal Investigator
  • Mar 2016 – Feb 2019
    NRG Oncology Network Group Operations Center
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Mar 2016 – Feb 2019
    NRG Oncology network group operations center
    NRG ONCOLOGY FOU · Principal Investigator
  • Dec 2015 – Jan 2020
    miscellaneous donors
    MISCELLANEOUS DONORS · Principal Investigator
  • Oct 2015 ACTIVE
    NSABP Foundation Subcontract
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Oct 2015 – Feb 2016
    NRG Oncology Network Group Operations Center
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Apr 2015 – Jun 2016
    A Multi-Center Study of the Brutons Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors
    Pharmacyclics, Incorporated · Principal Investigator
  • Mar 2015 – Feb 2019
    Molecular Analysis for Therapy Choice (MATCH)
    NRG ONCOLOGY FOU · Principal Investigator
  • Feb 2015 – Feb 2018
    293An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Chemotherapy
    TAIHO PHARMACEUTICAL · Principal Investigator
  • Feb 2015 ACTIVE
    UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Feb 2015 – Jan 2020
    UF Health Cancer Center Collaborative Cancer Related Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Sep 2014 – Aug 2019
    Florida Minority Cancer Research and Training Center: Feasibility Studies
    NATL INST OF HLTH NCI · Co-Investigator
  • Sep 2014 – Feb 2019
    A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
    NRG ONCOLOGY FOU · Principal Investigator
  • Jul 2014 – Jul 2017
    Single Agent Adjuvant Aflibercept (ziv-Aflibercept) for Patients with Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study
    LIFESPAN RHODE ISLAND HOSPITAL · Principal Investigator
  • Jun 2014 – Jun 2017
    A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
    CELGENE CORP · Principal Investigator
  • May 2014 – May 2018
    Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
    SOUTHWEST ONCOLOGY GROUP · Principal Investigator
  • Apr 2014 – Aug 2018
    A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Mar 2014 – Feb 2019
    Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
    NRG ONCOLOGY FOU · Principal Investigator
  • Jan 2014 – Jan 2017
    A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute?-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
    NEW LINK GENETICS · Principal Investigator
  • May 2013 – May 2017
    A Phase IB Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
    INCYTE CORPORATION · Principal Investigator
  • Feb 2013 – Feb 2020
    NSABP Patient Registry and Biospecimen Profiling Repository
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Jan 2013 ACTIVE
    Determination of predictive biomarker for dasatinib use in combination with Chemotherapy in advanced pancreatic cancer
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Nov 2012 – Nov 2017
    Phase II study of 5-fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Jul 2012 – Jul 2020
    A Pase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Prepoperative Combined Modaligy Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Aug 2011 ACTIVE
    Sorafenib plus Capecitabine (SorCape) in previously treated metastatic colorectal cancer
    BAYER HEALTHCARE PHARMACEUTICALS · Principal Investigator
  • Jan 2011 – Jun 2017
    A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute?-Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer
    NEW LINK GENETICS · Principal Investigator
  • Nov 2008 – Nov 2017
    A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with
    NATL SURG ADJUV BREAST & BOWEL · Principal Investigator
  • Jul 2007 – Aug 2016
    Clinical and Translational Science Institute
    UF RESEARCH FOU · Project Manager
  • Dec 2002 – Dec 2017
    (ACOSOG) Z9001: PHASE III RNDMZD DOUBLE-BLIND STUDY OF ADJUVANT ST1571 (GLEEVER TM) VS PLACEBO IN PATIENTS FOLLOWING THE
    DUKE UNIV · Principal Investigator
Education:
  • 2005
    Fellowship – Hematology and Oncology
    University of Florida
  • 2001
    Residency – Internal Medicine
    University of Florida
  • 1999
    Internship – Internal Medicine
    University of Florida
  • 1998
    Doctor of Medicine w/ Honors
    University of Florida
  • 1994
    Bachelor of Science w/ Highest Honors
    University of Florida
Christopher R Cogle

Christopher R Cogle M.D.

Professor
Department: MD-HEMATOLOGY/ONCOLOGY
Phone: (352) 273-7493

Christopher R. Cogle, M.D. is a practicing oncologist, distinguished scientist, and leader in health policy with focus on cancer and cardiovascular diseases. Dr. Cogle’s clinic is designated a Center of Excellence by the MDS Foundation. Dr. Cogle has been named a Scholar in Clinical Research by the Leukemia & Lymphoma Society. In 2020, the National Academy of Medicine distinguished Dr. Cogle as an Emerging Leader in Health and Medicine Scholar.

Accomplishments:
  • Emerging Leader in Health and Medicine Scholar
    2020 · National Academy of Medicine
  • Clinical Trials Award
    2018 · UF Health Cancer Center
  • Research Prize
    2016 · Harvard Business School Precision Trials Challenge
  • Research Prize
    2016 · UF Department of Medicine
  • Research Prize
    2014 · UF Department of Medicine
  • Customer Service Key Award for Excellent Patient Care
    2013 · UF Health Shands Hospital
  • Bench to Bedside Award
    2012 · University of Florida
  • Research Award
    2012 · UF Department of Medicine
  • Scholar in Clinical Research
    2012 · Leukemia and Lymphoma Society
  • Best in Research
    2011 · University of Florida
  • Center of Excellence in Myelodysplastic Syndromes
    2009 · MDS Foundation
  • Excellence in Teaching Award
    2008 · University of Florida
  • Best in Research
    2006 · University of Florida
  • Top 10 US Young Stem Cell Scientist
    2005 · British Council
  • First Prize in Research
    2004 · Joint Cancer Conference of the Florida Universities
  • Young Investor Award
    2003 · American Society of Clinical Oncology
  • NIH Loan Repayment Award
    2002 · NIH
  • Alpha Omega Alpha
    1998 · Alpha Omega Alpha
  • Vigil Honor
    1989 · Order of the Arrow
  • Eagle Scout
    1987 · Boy Scouts of America
Certifications:
  • Oncology
    American Board of Internal Medicine
Specialties:
  • Medicine
Subspecialties:
  • Oncology
Clinical Interests:
  • Acute myeloid leukemia (AML) – children
  • Acute myeloid leukemia – adult
  • Aplastic anemia
  • Bone marrow aspiration
  • Bone marrow biopsy
  • Bone marrow culture
  • Bone marrow transplant
  • Cancer – resources
  • Cancer treatment information
  • Cord blood transplantation
  • Diet – cancer treatment
  • Diet and cancer
  • Genetics
  • Myelodysplastic Syndromes (MDS)
  • Myelodysplastic syndrome
  • Secondary aplastic anemia
  • Stem cell research
Research Summary:

Christopher R. Cogle, M.D. is a physician and scientist with research focus on cancer and health policy. In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. In his mid career, as a Leukemia & Lymphoma Society Scholar in Clinical Research, he began translating research discoveries into investigator-initiated clinical trials. Dr. Cogle has also made major discoveries in cancer epidemiology and was elected to lead Florida’s cancer prevention and control efforts at the state level, producing the Florida Cancer Plan, leading statewide campaigns for improved cancer prevention and control, and advising the Florida Legislature, Florida Secretary of Health, and Florida Governor on evidence-based strategies to reduce the state’s cancer burden. In 2020, Dr. Cogle was selected by the National Academy of Medicine as an Emerging Leader in Health and Medicine Scholar. As a Scholar he works to increase access to high quality health care by studying and improving health policies of government entities and health systems.

Research Interests:
  • Allogeneic Hematopoietic Cell Transplantation
  • Bone marrow transplantation
  • Cancer
  • Cancer Genetics
  • Cancer Informatics
  • Cancer Screening
  • Cancer prevention
  • Digital Health
  • Genetics
  • Haplo-identical Stem Cell Transplantation
  • Health Outcomes
  • Health Policy
  • Health outcomes research
  • Healthcare policies
  • Leukemia
  • Population Health
  • Targeted Cancer Therapy
  • Telehealth
  • health services research
Publications: